institution between 2004 and 2016 and receiving treatment with chemoimmunotherapy. Progression-free survival (PFS) and global survival (OS) rates were estimated using the method of Kaplan-Meier. Univariate and multiple Cox regression models were used to assess the effect of covariates on PFS and OS. Results: Median (range) age at diagnosis was 62 years (32-83). Forty-eight percent of patients had high-risk FLIPI and 36.7% were high-risk FLIPI-2. Patient characteristics are shown in the Table 1. The most commonly front-line therapies administered were R-CHOP (56.9%) and R-CVP (40%). Rituximab maintenance was administered to 48 patients (73.8%). Overall, 67.2% of patients achieved complete remission (CR) and 12.5% partial remission (PR) with no significant differences between both regimens. After a median follow-up of 60 months (range, 0-185), 67.7% of patients are still in CR, 15.4% have relapsed, and 23.1% have died. Neither the median PFS nor the median OS were reached. The estimated 5-year PFS and OS among all patients were 67.4% and 83.4%, respectively. Variables influencing PFS and OS in the univariate analysis were age > 60 years (p = 0.02), Hb <12 g/dL (p = 0.036), raised serum LDH (p = 0.001), albumin <3 mg/dL (p = 0.029), high-risk FLIPI (p = 0.01), high-risk FLIPI-2 (p = 0.001), not receive Rituximab maintenance (p = 0.04), disease progression <2 years after diagnosis (p < 0.0001), and disease refractoriness (p < 0.0001). Multivariate analysis confirmed raised serum LDH (p = 0.034) and refractoriness to front-line therapy (p = 0.021) as the two variables affecting OS while disease progression <2 years after diagnosis was the only variable affecting PFS (p = 0.007). Conclusions: Our results show that refractoriness to chemoimmunotherapy and early progression after treatment were the most relevant variables affecting outcome of patients. Both factors should be used to stratify the risk of patients with FL. Likewise, we did not found any OS and PFS advantage among patients receiving maintenance. UNL, upper normal limit.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.